Rheumatology Book

http://www.fpnotebook.com/

AnakinraAka: Kineret

Advertisement

  1. Indications
    1. Severe active Rheumatoid Arthritis refractory to DMARDs
  2. Contraindications
    1. Chronic or acute infection
    2. Concurrent use of TNF antagonists (infection risk)
      1. Adalimumab (Humira)
      2. Etanercept (Enbrel)
      3. Infliximab (Remicade)
  3. Mechanism
    1. Interleukin-1 Receptor Antagonist
  4. Dosing
    1. Adults: 100 mg SC qd with rotating injection sites
  5. Cost
    1. Vial of 100 mg/0.67 ml (7 doses): $260
  6. Adverse Effects
    1. Immunosuppression
      1. Use caution in any patient prone to infection
    2. Headache
    3. Injection site inflammation
    4. Gastrointestinal upset
    5. Leukopenia (including Neutropenia)
  7. Monitoring
    1. Serum Creatinine
    2. Complete Blood Count with Neutrophil Count
      1. Baseline, then
      2. Monthly for 3 months, then
      3. Quarterly
  8. References
    1. (2003) Lexicomp Drug Database

anakinra (C0245109)

Definition (MSH)A synthetic form of native human IL-1Ra that has an additional methionine residue at its amino terminus.
Definition (PDQ)A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43007&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43007&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38717" NCI Thesaurus)
Definition (NCI)A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)
ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSHD053590
Englishanakinra, ANAKINRA PREPARATION
Spanishanakinra
Parent ConceptsInterleukin 1 Receptor Antagonist Protein (C1704264), Other antirheumatics (C0973578), Unclassified Ingredients (C1372954), Drug allergen (C1320237), Immunomodulators (C1527392), Immune Suppressants (Non-TNF Inhibitors) (C1579325)
SourcesMSH, MTH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Kineret (C1170364)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD053590
EnglishAmgen Brand of Anakinra, Anakinra Amgen Brand, Kineret
SourcesMSH, NCI, PDQ, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree